"AdAlta identified the Chinese opportunity early, and it is now in the middle of one of the year's biggest biotech macro themes"

Jason Segal, The Armchair Analyst, recently put our "East to West" strategy in context as part of an article titled: The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'.

https://thearmchairanalyst.com/p/the-moment-that-chinese-biotechs-went-from-too-hard-to-too-hard-to-ignore

He concluded his Investment Memo saying: 1AD isn’t just about its cancer asset, it’s a bet on the overall East-to-West strategy and the inherent value of the listed vehicle.